Kenvue Inc. (KVUE)
- Previous Close
23.38 - Open
23.50 - Bid --
- Ask --
- Day's Range
23.18 - 23.72 - 52 Week Range
17.67 - 24.46 - Volume
6,172,190 - Avg. Volume
17,199,365 - Market Cap (intraday)
45.291B - Beta (5Y Monthly) --
- PE Ratio (TTM)
43.71 - EPS (TTM)
0.54 - Earnings Date May 8, 2025
- Forward Dividend & Yield 0.82 (3.51%)
- Ex-Dividend Date May 14, 2025
- 1y Target Est
24.27
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
www.kenvue.com22,000
Full Time Employees
December 29
Fiscal Year Ends
Sector
Industry
Recent News: KVUE
View More
Performance Overview: KVUE
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KVUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KVUE
View MoreValuation Measures
Market Cap
44.86B
Enterprise Value
52.51B
Trailing P/E
43.30
Forward P/E
20.33
PEG Ratio (5yr expected)
2.39
Price/Sales (ttm)
2.91
Price/Book (mrq)
4.64
Enterprise Value/Revenue
3.40
Enterprise Value/EBITDA
21.28
Financial Highlights
Profitability and Income Statement
Profit Margin
6.67%
Return on Assets (ttm)
6.88%
Return on Equity (ttm)
9.87%
Revenue (ttm)
15.45B
Net Income Avi to Common (ttm)
1.03B
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
90.18%
Levered Free Cash Flow (ttm)
1.62B
Research Analysis: KVUE
View MoreResearch Reports: KVUE
View MoreLooking for more favorable entry point
Kenvue Technologies Inc., formerly part of Johnson & Johnson, is a pure-play consumer health company. The company has three segments: Self Care, Skin Health & Beauty, and Essential Health. Major brands include Tylenol, Nicorette, Zyrtec, Neutrogena, Aveeno, Listerine, and Band-Aid. The company has 22,000 employees. KVUE shares are a component of the S&P 500.
RatingPrice TargetIt's a rough day on Wall Street. The major indices are plunging
It's a rough day on Wall Street. The major indices are plunging with the Nasdaq down 3.5% at midday. The pessimism follows comments by President Trump that it is possible for the U.S. to slip into a recession as he deploys his macroeconomic policies including tariffs. The yield on the 10-year Treasury note is at 4.21%. Oil is at $67 per barrel. Bitcoin is off again and is near $80,000.
Kenvue Earnings: Distribution Issues and Weak Demand Temper Results, but Recovery Underway
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
RatingPrice TargetKenvue Earnings: Distribution Issues and Weak Demand Temper Results, but Recovery Underway
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
RatingPrice Target